Metagenomi Adenine Base Editor (ABE) demonstrates no detectable translocations and no significant genomic base composition differences in primary T-cells Metagenomi is a precision genetic medicines ...
Growing focus on gene-based therapies, advances in editing tools, and increasing research investments are accelerating the adoption of genome editing technologies across life sciences and agriculture.
Genetic disorders occur due to alterations in the primary genetic material—deoxyribonucleic acid (DNA)—of an organism.
Understanding human gene function in living organisms has long been hampered by fundamental differences between species.
Advancements in genome editing technologies the growing emphasis on safe and accurate gene correction, and strong biotechnology R&D investment drive the base editing market.Austin, Texas, Jan. 21, ...
A new genome editing tool—minimal versatile genetic perturbation technology (mvGPT)—can achieve simultaneous and orthogonal gene editing and gene regulation in human cells. The coming together of ...
Recent scientific advances have made genome editing technologies—a suite of biological tools for making precise additions, deletions, and alterations to the DNA and RNA of living cells– more rapid, ...
The National Institutes of Health will launch a research program to encourage the development of genome-editing treatments for various diseases. Under the Somatic Cell Genome Editing program, the NIH ...
Metagenomi is a precision genetic medicines company committed to developing curative therapeutics for patients using its proprietary, comprehensive metagenomics-derived toolbox. Metagenomi is ...
Recent scientific advances have made genome editing technologies—a suite of biological tools for making precise additions, deletions, and alterations to the DNA and RNA of living cells– more rapid, ...
MGX-001, utilizing a highly specific and efficient MG29-1 nuclease, exhibits no identifiable off-target editing MG29-1 nuclease targeting the albumin safe harbor locus showed no evidence of ...